The genetic basis of colorectal cancer: Insights into critical pathways of tumorigenesis

Gastroenterology

Volumn 119, Issue 3, 2000, Pages 854-865

  Chung, Daniel C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYCLOOXYGENASE 2; DNA METHYLTRANSFERASE; GUANINE NUCLEOTIDE BINDING PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROTEIN BAX; PROTEIN P53; PROTEIN TYROSINE KINASE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANIMAL MODEL; ARTICLE; CHROMOSOME 18Q; COLON CARCINOGENESIS; COLORECTAL CANCER; DNA REPAIR; FAMILY HISTORY; GENE MAPPING; GENE MUTATION; GENETIC MODEL; HETEROZYGOSITY LOSS; HUMAN; MOUSE; NONHUMAN; ONCOGENE K RAS; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0033858528     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2000.16507     Document Type: Article

References (125)

1. A genetic model for colorectal tumori-genesis
2. Ras: A versatile cellular switch
3. The role of p21ras in receptor tyrosine kinase signalling
4. p53: Puzzle and paradigm
5. Signaling to p53: Breaking the MDM2-p53 circuit
6. Identification and characterization of the familial adenomatous polyposis coli gene
7. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients
8. Characteristics of somatic mutation of the adenomatous polyposis coli gene in colorectal tumors
9. Association of the APC tumor suppressor protein with catenins
10. Association of the APC gene product with β-catenin
11. Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta
12. Alleles of APC modulate the frequency and classes of mutations that lead to colon polyps
13. Somatic mutations of the APC gene in colorectal tumors: Mutation cluster region in the APC gene
14. Molecular diagnosis of familial adenomatous polyposis
15. APC mutations occur early during colorectal tumorigenesis
16. Restriction of ocular fundus lesions to a specific subgroup of APC mutations in adenomatous polyposis coli patients
17. Familial adenomatous polyposis: Desmoid tumors and lack of ophthalmic lesions (CHRPE) associated with APC mutations beyond codon 1444
18. Alleles of the APC gene: An attenuated form of familial polyposis
19. The clinical correlates of a 3' truncating mutation (codons 1982-1983) in the adenomatous polyposis coli gene
20. Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC
21. Lessons from hereditary colorectal cancer
22. Binding of GSK3β to the APC-β-catenin complex and regulation of complex assembly
23. Identification of c-MYC as a target of the APC pathway
24. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells
25. Target genes of beta-catenin-T-cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas
26. The metalloproteinase matrilysin is a target of β-catenin transactivation in intestinal tumors
27. PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs
28. Mutational analysis of the APC/β-catenin/Tcf pathway in colorectal cancer
29. Beta-catenin mutations are more frequent in small colorectal adenomas than in larger adenomas and invasive carcinomas
30. Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin of APC
31. Neoplastic transformation of RK3E by mutant β-catenin requires deregulation of Tcf/Lef transcription but not activation of c-myc expression
32. A betacatenin mutation in a sporadic colorectal tumor of the RER phenotype and absence of beta-catenin germline mutations in FAP patients
33. Frequent frameshift mutations of the TCF-4 gene in colorectal cancers with microsatellite instability
34. The TAK1-NLK-MAPK-related pathway antagonizes signalling between β-catenin and transcription factor TCF
35. Regulation of β-catenin signaling by the B56 subunit of protein phosphatase 2A
36. Alterations of the PPP2R1B gene in human lung and colon cancer
37. The adenomatous polyposis coli tumor suppressor protein localizes to plasma membrane sites involved in active cell migration
38. Binding of APC to the human homolog of the Drosophila discs large tumor suppressor protein
39. Apc1638T: A mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development
40. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene
41. Loss of APC heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Apc gene
42. Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene
43. DNA mismatch repair and cancer
44. Clinical findings with implications for genetic testing in families with clustering of colorectal cancer
45. Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients
46. Biochemistry and genetics of eukaryotic mismatch repair
47. A National Cancer Institute workshop in microsatellite instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer
48. Somatic mutations in the hMSH2 gene in microsatellite unstable colorectal carcinomas
49. Microsatellite instability and the role of hMSH2 in sporadic colorectal cancer
50. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability
51. MSH2 and MLH1 mutations in sporadic replication error-positive colorectal carcinoma as assessed by two-dimensional DNA electrophoresis
52. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer
53. Mutations predisposing to hereditary nonpolyposis colorectal cancer: Database and results of a collaborative study
54. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis
55. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma
56. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing MSl cancers
57. A naturally occurring hPMS2 mutation can confer a dominant negative mutator phenotype
58. Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer
59. Tumorigenesis in Mlh1 and MIh1/Apc1638N mutant mice
60. HNPCC-like cancer predisposition in mice through simultaneous loss of Msh3 and Msh6 mismatch-repair protein functions
61. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability
62. Effects of growth factors on an intestinal epithelial cell line: Transforming growth factor beta inhibits proliferation and stimulates differentiation
63. Tumor suppressor activity of the TGF-β pathway in human cancers
64. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype
65. Microsatellite instability in the insulin-like growth factor II receptor gene in gastrointestinal tumours
66. Mutations of E2F-4 trinucleotide repeats in colorectal cancer with microsatellite instability
67. Frameshift mutations at mononucleotide repeats in caspase-5 and other target genes in endometrial and gastro-intestinal cancer of the microsatellite mutator phenotype
68. CDX2, a human homologue of Drosophila caudal, is mutated in both alleles in a replication error positive colorectal cancer
69. Frameshift mutator mutations
70. The insulin-like growth factor II receptor gene is mutated in genetically unstable cancers of the endometrium, stomach, and colorectum
71. Molecular nature of colon tumors in hereditary nonpolyposis colon cancer, familial polyposis, and sporadic colon cancer
72. Frequent mutation of betacatenin and APC genes in primary colorectal tumors from patients with hereditary nonpolyposis colorectal cancer
73. Accumulated clonal genetic alterations in familial and sporadic colorectal carcinomas with widespread instability in microsatellite sequences
74. Alternative genetic pathways in colorectal carcinogenesis
75. Genetic instability in colorectal cancers
76. Mutations of mitotic checkpoint genes in human cancers
77. TGF-beta signalling from cell membrane to nucleus through SMAD proteins
78. Identification of regulatory sequences in the type I plasminogen activator inhibitor gene responsive to transforming growth factor β
79. Transforming growth factor β activates the promoter of cyclin-dependent kinase inhibitor p15INK4B through an Sp1 consensus site
80. Functional analysis of the transforming growth factor β responsive elements in the WAF1/Cip1/p21 promoter
81. Transforming growth factor-β1 inhibits cyclin D1 expression in intestinal epithelial cells
82. Autoinduction of transforming growth factor β1 is mediated by the AP-1 complex
83. Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers
84. Somatic alterations of the DPC4 gene in human colorectal cancers in vivo
85. MADR2 maps to 18q21 and encodes a TGF-beta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma
86. Genetic alterations during colorectal-tumor development
87. Frequency of Smad gene mutations in human cancers
88. Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes
89. HNPCC associated with germline mutation in the TGF-β type II receptor gene
90. Association of K-ras mutations with p16 methylation in human colon cancer
91. Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27KIP1
92. Oncogenic ras induces gastrin gene expression in colon cancer
93. Aberrant crypt foci of the colon as precursors of adenoma and cancer
94. The DCC gene: Structural analysis and mutations in colorectal carcinomas
95. The DCC protein and prognosis in colorectal cancer
96. Induction of apoptosis and G2/M cell cycle arrest by DCC
97. Activating SRC mutation in a subset of advanced human colon cancers
98. Differentiation and reversal of malignant changes in colon cancer through PPARγ
99. Activation of PPARγ leads to inhibition of anchorage-independent growth of human colorectal cancer cells
100. + mice
101. Activators of the nuclear receptor PPARγ enhance colon polyp formation
102. Loss-of-function mutations in PPARγ associated with human colon cancer
103. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
104. G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2
105. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
106. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2
107. Suppression of intestinal polyposis in Apc delta 716 knockout mice by inhibition in cyclooxygenase 2 (COX-2)
108. - mice
109. Inuslinlike growth factors and binding proteins in colon cancer
110. Post-translational processing of gastrin in neoplastic human colonic tissues
111. Expression but incomplete processing of progastrin in colorectal carcinomas
112. Allelotype of colorectal carcinomas
113. Mapping of a target region of allelic loss to a 0.5-cM interval on chromosome 22q13 in human colorectal cancer
114. Hypomethylation of DNA from benign and malignant human colon neoplasms
115. Cancer epigenetics comes of age
116. Hypermethylation of the p16 gene in sporadic T3NOMO stage colorectal cancers: Association with DNA replication error and shorter survival
117. High expression of the DNA methyltransferase gene characterizes human neoplastic cells and progression stages of colon cancer
118. Expression of an exogenous eukaryotic DNA methyltransferase gene induces transformation of NIH 3T3 cells
119. Suppression of intestinal neoplasia by DNA hypomethylation
120. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors
121. Mutations of the p53 gene in the stool of patients with resectable colorectal cancer
122. Allelic loss of chromosome 18q and prognosis in colorectal cancer
123. Competency in mismatch repair prohibits clonal expansion of cancer cells treated with N-methy-N-nitro-N-nitrosoguanidine
124. Disruption of p53 in human cancer cells alters the responses to therapeutic agents
125. Aspirin use and potential mechanisms for colorectal cancer prevention